| 20.61 Data as of May 21 |  +1.01 / +5.15%Today’s Change | 10.85 Today|||52-Week Range 20.64 | +71.18% Year-to-Date |
| Actavis to Buy Warner Chilcott - Analyst Blog May 21 / Zacks.com | Actavis/Warner Chilcott: simple medicine May 20 / FT.com |
| The Deal: Actavis Extends Gains Following Warner Deal May 21 / TheStreet.com | The biggest merger you didn't hear about today May 20 / Fortune |
| Warner Chilcott Reaches New 52-Week High (WCRX) May 21 / TheStreet.com | Warner Chilcott Rises On Unusually High Volume (WCRX) May 20 / TheStreet.com |
| Actavis: The latest Fortune 500 company to "leave" the U.S. for tax reasons May 21 / Fortune | The Deal: Actavis Plays Hunter in $8.5 Billion Deal for Ireland's Warner Chilcott May 20 / TheStreet.com |
| Ireland Welcomes Watson Pharmaceuticals, an American Success May 20 / TheStreet.com | Actavis to acquire Warner Chilcott in $5bn pharmaceutical deal May 20 / FT.com |
| Previous close | 19.60 |
| Today’s open | 19.63 |
| Day’s range | -- - -- |
| Volume | 24,529,512 |
| Average volume (3 months) | 6,211,633 |
| Market cap | $4.9B |
| Dividend yield | 2.43% |
| Earnings growth (last year) | +140.30% |
| Earnings growth (this year) | -18.22% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | -6.86% |
| P/E ratio | -- |
| Price/Sales | 1.18 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| IDXXIDEXX Laboratories I... | -0.09 | -0.11% |
| SGENSeattle Genetics Inc | -0.02 | -0.06% |
| ALKSAlkermes Plc | +0.94 | +3.03% |
| PCYCPharmacyclics Inc | +2.85 | +3.48% |
| Next reporting date | August 9, 2013 |
| EPS forecast (this quarter) | $0.85 |
| Annual revenue (last year) | $2.5B |
| Annual profit (last year) | $403.0M |
| Net profit margin | 15.86% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
President, Chief Executive Officer & Director Roger M. Boissonneault |
Chief Financial Officer, Director & Executive VP Paul S. Herendeen, MBA |
Corporate headquarters Dublin, Dublin |
.
